Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 4, 2011, Pages 476-485

  Camacho Marti V ^a   Marquie M ^a   Lleo A ^a,b   Alves L ^a   Artigas, C ^a   Flotats, A ^a   Duch, J ^a   Blesa, R ^a,b   Gomez Isla T ^a,b   Carrio I ^a   Estorch, M ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

3 Iodobenzylguanidine; Dementia; Lewy body disease; Scintigraphy; Tomography, emission computed, single photon

Indexed keywords

FLUOROPROPYL CARBOMETHOXY 3BETA(4 IODOPHENYLTROPANE) I 123; METAIODOBENZILGUANIDINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL GANGLION; CARDIAC SYMPATHETIC IMPAIRMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; FEMALE; HEART; HEART DISEASE; HUMAN; MALE; MEDIASTINUM; MEDICAL HISTORY; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT CARE; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; BASAL GANGLIA; FEMALE; HEART DISEASES; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STRIATONIGRAL DEGENERATION; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 80755188037     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28. (Pubitemid 38018924)
2. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72. (Pubitemid 43970103)
3. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24. (Pubitemid 26374873)
4. Lopez OL, Becker JT, Kaufer DI, Hamilton RL, Sweet RA, Klunk W et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59:43-6. (Pubitemid 34052554)
5. Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, Ballard C. Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. Dement Geriatr Cogn Disord 2008;25:195-205. (Pubitemid 351363882)
6. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583-8. (Pubitemid 33010570)
7. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-92. (Pubitemid 34224938)
8. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B et al. Myocardial imaging in man with I-123 metaiodobenzylguanidine. J Nucl Med 1981;22:129-32. (Pubitemid 11143204)
9. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007;17:24-30.
10. Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann.Nucl.Med. 2004 Sep;18:453-461. (Pubitemid 39410243)
11. Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008;35:1636-41.
12. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66.1850-4.
13. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 2008;35 Suppl 1:S51-7.
14. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123) I-labelled dopamine D(2) receptor ligands. Eur J Nucl Med Mol Imaging 2002;29:BP23-29. (Pubitemid 44392227)
15. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999 Aug; 122 (Pt 8):1449-68. (Pubitemid 29374123)
16. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-81. (Pubitemid 350057277)
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
18. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernandez G et al. Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia 2001;39:1150-7. (Pubitemid 32799144)
19. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
20. Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N, Aguilar M, Casas L, Molinuevo JL et al. Spanish Multicenter Normative Studies (NEURONORMA Project): norms for Boston naming test and token test. Arch Clin Neuropsychol 2009;24:343-54.
21. Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N, Quintana-Aparicio M, Aguilar M, Badenes D et al. Spanish Multicenter Normative Studies (NEURONORMA Project): norms for verbal fluency tests. Arch Clin Neuropsychol 2009;24:395-411.
22. Reisberg B, Ferris SH, de Leon MJ, Crook T The Global Deterioration Scale for assessment of primary degenerative dementia. Am.J.Psychiatry 1982;139:1136-9. (Pubitemid 12051593)
23. Binetti G, Locascio JJ, Corkin S, Vonsattel JP, Growdon JH. Differences between Pick disease and Alzheimer disease in clinical appearance and rate of cognitive decline. Arch Neurol 2000;57:225-32. (Pubitemid 30097191)
24. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 2004;19:203-14. (Pubitemid 38316871)
25. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM et al. Screening for dementia with the memory impairment screen. Neurology 1999;52:231-8. (Pubitemid 29059044)
26. Teunisse S, Derix MM. The interview for deterioration in daily living activities in dementia: agreement between primary and secondary caregivers. Int Psychogeriatr 1997;9 Suppl 1:155-62. (Pubitemid 28045354)
27. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G, EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008:35:1039-47.
28. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:443-50.
29. Estorch M, Carrió I, Bernà L, López-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126-32.
30. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503-10. (Pubitemid 30333223)
31. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75-94. (Pubitemid 34196234)
32. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:249-51. (Pubitemid 40143717)
33. Kashihara K, Yamamoto M. Myocardial (123)I-MIBG scintigraphy in patients with PSP, CBD and MSA. J Neurol 2006;253 Suppl 3:iii35-iii40.
34. Novellino F, Bagnato A, Salsone M, Cascini GL, Nicoletti G, Arabia G et al. Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy Bodies Disease from FTD. Neurobiol Aging 2009 Jan 8.
35. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33:248-53.
36. Oide T, Tokuda T, Momose M, Oguchi K, Nakamura A, Ohara S et al. Usefulness of [123I]metaiodobenzylguanidine ([123I] MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003;42:686-90. (Pubitemid 37021200)
37. Suzuki M, Kurita A, Hashimoto M, Fukumitsu N, Abo M, Ito Y et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006;240:15-9. (Pubitemid 41814948)
38. Lindboe CF, Hansen HB. The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 1998;17:204-9. (Pubitemid 28332668)
39. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-91. (Pubitemid 29480089)
40. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007:6:305-13. (Pubitemid 46367938)
41. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25. (Pubitemid 38747333)
42. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34 Suppl 1:S62-73. (Pubitemid 46956022)
43. Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005;20:552-61. (Pubitemid 40862252)
44. Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 2009 Jul 22.
45. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38Suppl 2:2-7. (Pubitemid 27453771)
46. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-71. (Pubitemid 29177934)
47. Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P, Wenger S et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6. (Pubitemid 27026988)